- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
- Drug · Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- ASP1617, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, 18F-Florbetaben
- Drug
- Lead sponsor
- Adam Brickman
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chlamydial Infections
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 14 Years to 44 Years
- Enrollment
- 4,878,935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Cetuximab, Ulixertinib, Encorafenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- PCV, Polypoidal Choroidal Vasculopathy
- Interventions
- high-dose ranibizumab, ranibizumab
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 25 Years to 95 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- tanespimycin, cytarabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Rett Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 3 Years to 18 Years · Female only
- Enrollment
- 146 participants
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Renal Transplant Recipients With Anti-HLA Antibodies
- Interventions
- Not listed
- Lead sponsor
- Databean
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Chronic Disease Self-management Program (CDSMP)
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL)
- Interventions
- TRU-016 (anti-CD37 protein therapeutic)
- Drug
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Severe Hepatic Impairment
- Interventions
- Vortioxetine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis
- Interventions
- Deucravacitinib, Apremilast
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
- Interventions
- BMF-219
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- 64Cu-SAR-BBN, 67Cu-SAR-BBN
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
- Conditions
- Ulcerative Colitis
- Interventions
- Etrozulimab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- XB371
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Rogers, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Pulmonary Embolism, Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- SEARCH algorithm
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Fresno, California • Irvine, California • Los Angeles, California + 5 more
- Conditions
- HLHS
- Interventions
- Longeveron Mesenchymal Stem Cells
- Biological
- Lead sponsor
- Longeveron Inc.
- Industry
- Eligibility
- 1 Day to 1 Year
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio + 1 more
- Conditions
- Osteoarthritis, Knee, Pain
- Interventions
- Knee Osteoarthritis, Healthy Control
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Castrate Resistant Prostate Cancer
- Interventions
- Docetaxel, Radium 223
- Drug · Radiation
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio